Abstract
Background:
Botulinum toxin (BoNT) type A, commonly known by its brand name Botox, has gained widespread recognition as a therapeutic intervention for conditions such as blepharospasm and hemifacial spasm. These conditions are classified as focal dystonias and are characterized by involuntary muscle contractions that can cause both functional disabilities and cosmetic concerns for those affected.
Objective:
The primary aim of this study was to comprehensively assess the efficacy, safety, and tolerability profile of Botulinum toxin in a cohort of 21 patients, comprised of 16 individuals diagnosed with blepharospasm and 5 with hemifacial spasm.
Methods:
Each patient underwent a series of Botox injections tailored to their specific condition and symptom severity. Following the administration of the treatment, participants were closely monitored over a six-month period to evaluate clinical outcomes and any potential adverse effects.
Results:
The treatment with Botulinum toxin resulted in a significant reduction in the frequency and intensity of involuntary muscle contractions in all participants. Furthermore, patients reported substantial improvements in their quality of life, indicating enhanced daily functioning and overall well-being. Notably, the treatment was generally well-tolerated, with only a few mild side effects, suggesting that adverse reactions were minimal and manageable.
Conclusion:
The findings from this study bolster the evidence supporting the use of Botulinum toxin as an effective first-line treatment option for individuals suffering from both blepharospasm and hemifacial spasm. The promising results highlight its role in alleviating symptoms and improving the quality of life for patients affected by these challenging conditions.
Keywords: botulinum toxin, BoNT, blepharospasm, hemifacial spasm
1. BACKGROUND
Blepharospasm and hemifacial spasm are two distinct focal dystonia types leading to involuntary muscle contractions. Blepharospasm involves the orbicularis oculi muscle, resulting in involuntary eyelid closure. At the same time, hemifacial spasm affects the muscles on one side of the face, often caused by vascular compression of the facial nerve. These conditions can severely impair vision, facial expression, and social interactions, significantly reducing quality of life (1).
The treatment of choice for both conditions is botulinum toxin type A (Botox), which works by inhibiting the release of acetylcholine at the neuromuscular junction, resulting in muscle relaxation. BoNT has demonstrated efficacy in both blepharospasm and hemifacial spasm, and its use has become well-established in clinical practice. However, most published studies involve larger cohorts, and data from smaller, more targeted studies remain valuable for clinical refinement. Our study reports the outcomes of 16 patients with blepharospasm and five with hemifacial spasm treated with botulinum toxin.
2. OBJECTIVE
This study aimed to evaluate the efficacy, safety, and tolerability of BoNT in patients with blepharospasm and hemifacial spasm.
3. MATERIAL AND METHODS
Study Design and Patient Selection
This prospective observational study was conducted from January 2023 to October 2023 at the Eye Clinic Svjetlost in Sarajevo. A total of 21 patients were enrolled in the study, including 16 with blepharospasm and 5 with hemifacial spasm.
Inclusion Criteria:
Diagnosis of blepharospasm or hemifacial spasm based on established clinical criteria (2).
Age 18 years or older.
Provision of informed consent to participate in the study.
Exclusion Criteria:
Pregnancy or breastfeeding.
History of allergy to botulinum toxin.
Previous treatment with botulinum toxin within the past 3 months.
Severe systemic or neurological diseases that contraindicate the use of botulinum toxin.
Demographic data (age, gender, and disease duration) were collected for each patient.
Treatment Protocol
All patients received injections of botulinum toxin type A (Botox) as follows:
Blepharospasm Group (n=16): The orbicularis oculi muscle was injected bilaterally with 20 to 25 units per side, divided into 3 to 4 injection sites. Total doses ranged from 40 to 50 units.
Hemifacial Spasm Group (n=5): Injections were administered to the orbicularis oculi, zygomaticus, and orbicularis oris muscles on the affected side, with doses ranging from 30 to 50 units, depending on the severity of the spasm.
Patients were assessed at baseline, 1 month, 3 months, and 6 months post-treatment for symptom improvement and adverse effects. The primary outcome measure was symptom severity, evaluated using the Jankovic Rating Scale (Jankovic et al., 1988), where a reduction of at least 2 points was considered clinically significant. Patient satisfaction was also assessed using a Visual Analog Scale (VAS), ranging from 0 (very dissatisfied) to 10 (very satisfied).
Statistical Analysis
Data were analyzed using descriptive statistics. The mean reduction in Jankovic scores was calculated for each group. Chi-square tests were used to compare the incidence of side effects between the two groups. A p-value of less than 0.05 was considered statistically signifficant.
4. RESULTS
Demographic and Clinical Data
The study included 21 patients: 16 patients with blepharospasm (13 females and 3 males) and 5 patients with hemifacial spasm (3 females and 2 males). The mean age for patients with blepharospasm was 60.4 years (range: 45–75), while the mean age for those with hemifacial spasm was 58.2 years (range: 49–68). The mean duration of the disease for blepharospasm patients was 5.4 years (range: 2–15 years), and for hemifacial spasm patients, it was 6.2 years (range: 3–12 years).
Symptom Improvement
Blepharospasm Group: Thirteen out of 16 patients (81.3%) experienced a significant reduction in symptoms, with a mean decrease of 2.6 points on the Jankovic scale (p < 0.01). Improvement was observed within 1 to 2 weeks after treatment, and the effects lasted an average of 4.3 months before retreatment was needed.
Hemifacial Spasm Group: Four out of 5 patients (80%) reported a significant reduction in spasms, with a mean decrease of 2.4 points on the Jankovic scale (p < 0.01). Improvement was noted within 1 week of injection, and the effects lasted an average of 4.5 months before retreatment was required.
Patient Satisfaction
Blepharospasm Group: The mean patient satisfaction score was 8.1 out of 10, ranging from 5 to 10.
Hemifacial Spasm Group: The mean satisfaction score was 8.4 out of 10, with a range of 7 to 10.
Patients reported improvements in their ability to engage in daily activities. Those in the blepharospasm group noted enhancements in prolonged reading and watching TV, while individuals in the hemifacial spasm group felt they experienced better facial appearance and increased social comfort.
Side Effects
The most common side effect was ptosis (droopy eyelid), which occurred in 3 patients (18.8%) in the blepharospasm group and 1 patient (20%) in the hemifacial spasm group. The ptosis was mild and transient, resolving within 2 to 3 weeks.
Additionally, bruising at the injection site was observed in 4 patients (25%) in the blepharospasm group, but this resolved spontaneously within a few days. Dry eyes were reported in 2 patients (12.5%) in the blepharospasm group, which were managed with artificial tears. No serious adverse events, such as dysphagia or respiratory distress, were reported.
Duration of the Effect
Blepharospasm Group: The average duration of effect was 4.3 months, with a range of 3 to 5 months before retreatment was needed.
Hemifacial Spasm Group: The average duration of effect was 4.5 months, ranging from 4 to 6 months.
5. DISCUSSION
This study supports the efficacy and safety of botulinum toxin type A (Botox) for treating blepharospasm and hemifacial spasm. Consistent with previous research, botulinum toxin (BoNT) was effective in reducing symptom severity in both groups, with improvements noted within 1–2 weeks post-treatment (1,3). The mean reduction of 2.5 points on the Jankovic rating scale aligns with findings from larger trials, which consistently report a reduction of at least 50% in symptom severity (2). Recent studies have refined injection protocols for blepharospasm, focusing on optimal injection sites and dosing strategies. A review of the literature from 2019 to 2023 suggests that a combination of injections into the upper and lower orbicularis oculi muscles provides superior symptom relief (4). Additionally, individualized dosing based on symptom severity and patient response is becoming more preferred. Typical doses range from 10 to 25 units per side, with follow-up treatments every 3 to 6 months. Botulinum toxin injections are associated with rapid symptom improvement. A 2021 meta-analysis found that approximately 90% of patients experience significant relief within 2 weeks of treatment (5), solidifying botulinum toxin as the first-line treatment for blepharospasm. Botulinum toxin is also the treatment of choice for hemifacial spasm. A 2022 study by Liu et al. demonstrated that botulinum toxin effectively alleviated spasms in 80-90% of patients within a week of treatment, with effects lasting for 3 to 4 months (6). Common injection sites include the orbicularis oculi, zygomaticus, and orbicularis oris muscles. The safety profile of botulinum toxin in treating blepharospasm remains favorable. The most common adverse effects include eyelid ptosis, dry eye symptoms, and bruising at injection sites.
A study by Klein (7) found that ptosis occurred in about 15-20% of cases, although this side effect was usually transient and manageable. Recent research has focused on minimizing side effects by refining injection techniques, such as avoiding the lower eyelid and using smaller doses in patients with a history of ptosis. Consequently, overall patient satisfaction with botulinum toxin treatment for blepharospasm remains high, with both efficacy and safety continuing to improve. The side effect profile in our cohort was consistent with what is described in the literature, with ptosis and bruising being the most commonly reported adverse events. Ptosis is a well-known complication of botulinum toxin treatment, typically resulting from the diffusion of the toxin to nearby muscles (8). The transient nature of this side effect, along with its resolution within weeks, confirms the overall safety of the procedure. The duration of effect in our patients, lasting approximately 4.3–4.5 months, is also in line with the expected duration of action for BoNT (9), reinforcing the need for retreatment every 4–6 months.
6. CONCLUSION
The results of this study robustly endorse the use of botulinum toxin (BoNT) as an effective and front-line treatment option for both blepharospasm, a condition characterized by involuntary eyelid closures, and hemifacial spasm, which causes irregular contractions of the facial muscles. This treatment stands as a beacon of hope for those affected, offering them relief and restoring normalcy to their lives.
Author’s contribution:
The all authors were involved in preparation this article. All authors read and approved the final manuscript
Conflict of interest:
The authors declare that they have no competing interests
Financial support and sponsorship:
Nil.
REFERENCES
- 1.Hemphill JC, Greenberg SM, Anderson CS, et al. Smjernice za zbrinjavanje spontanog intracerebralno krvarenje: smjernica za zdravstvene djelatnike iz American Heart Association / American Stroke Association. Stroke. 2015;46:2032–2060. doi: 10.1161/STR.0000000000000069. [DOI] [PubMed] [Google Scholar]
- 2.Xiong Yu, Guo Xiumei, Xinyue, et al. Efficacy safety of tranexamic acid in intracranial haemorrhage: A meta-analysis. 2023 Mar 31;18(3):e0282726. doi: 10.1371/journal.pone.0282726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Jiao Xu, Li Mingfei, Li Lulu, Hu Xinyu, Guo Xiaohui, Lu Yun. Early Tranexamic Acid in Intracerebral Hemorrhage: A Meta-Analysis of Randomized Controlled Trials. SYSTEMATIC REVIEW article, Front. Neurol. 2021 December 06; doi: 10.3389/fneur.2021.721125. Sec. Endovascular and Interventional Neurology. Volume 12 -2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lu Yun, AY Fouda, Newsome AS, Spellicy S, Waller JL, Zhi W, Hess DC, et al. Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. Stroke. 2017;48(10):2885–2887. doi: 10.1161/STROKEAHA.117.018658. [DOI] [PubMed] [Google Scholar]
- 5.Law Zhe Kang, Menon Chaamanti Sivakumar, Woodhouse Lisa J, Philip Jason TICH-2 Investigators. Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial. 2024 Jul 30;:23969873241265939. doi: 10.1177/23969873241265939. Online ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–94. doi: 10.7326/0003-4819-151-4-200908180-00136. [DOI] [PubMed] [Google Scholar]
- 7.CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32. doi: 10.1016/S0140-6736(10)60835-5. [DOI] [PubMed] [Google Scholar]
- 8.Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2003;2:CD001245. doi: 10.1002/14651858.CD001245. [DOI] [PubMed] [Google Scholar]
- 9.Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;391:125–132. doi: 10.1016/S0140-6736(17)32455-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
